Seth M. Pollack, MD, discusses new strategies for converting immune-cold tumors, including the role of TLR4 agonists and IL-12–producing viral agents.
Seth M. Pollack, MD
Advertisement
Articles by Seth M. Pollack, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts Topical Gel sNDA for Superficial Basal Cell Carcinoma
2
Joining Commercialization and Innovation to Bring New Cancer Therapies
3
Remote Exercise Program for Patients With Metastatic Renal Cell Carcinoma Undergoing Immunotherapy: An EXIO Case Series Report
4
Bridging the "Survivorship Cliff" After Radiotherapy for Breast Cancer
5